A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

Trial Profile

A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Ganetespib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Biomarker
  • Acronyms MESO-02
  • Most Recent Events

    • 26 Oct 2016 Planned primary completion date changed from 1 May 2016 to 1 Sep 2017.
    • 08 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 May 2016, according to ClinicalTrials.gov record.
    • 20 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top